Anticancer drugs use evaluation: Limits of the approved labeling;Évaluation du bon usage des anticancéreux: Les limites des indications AMM

Bulletin du Cancer

Volumn 91, Issue 5, 2004, Pages 437-443

  Debrix, Isabelle ^a   André, Thierry ^a   Flahault, Antoine ^a   Kalu, Ogbe ^a   Gligorov, Joseph ^a   Lotz, Jean Pierre ^a   Milleron, Bernard ^a   Pene, Françoise ^a   Boukari, Yasmine ^a   Becker, Annie ^a  

^a HÔPITAL TENON   (France)

Author keywords

Anticancer drugs; Drug utilisation review; Off label used

Indexed keywords

5 FLUOROURACIL EPIRUBICIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIRARUBICIN; RALTITREXED; THIOTEPA; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER LOCALIZATION; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUSTRY; DRUG LABELING; DRUG USE; EVALUATION; HEALTH SURVEY; HOSPITAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOLOGY; RANDOMIZED CONTROLLED TRIAL; RARE DISEASE; SOLID TUMOR; NEOPLASM;

ANTINEOPLASTIC AGENTS; DRUG LABELING; DRUG UTILIZATION REVIEW; HUMANS; NEOPLASMS;

EID: 2942605809     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Carre-Auger E, Charpiat B. Off Label drug prescribing : a literature review. J Pharm Clin 1998 ; 17 : 187-94.
2. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non small cell cancer : European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990 ; 8 : 1556-62.
3. Sculier JP, Paesmans M, Thiriaux J, Lecomre J, Bureau G, Giner V et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patient with advanced non small cell cancer. J Clin Oncol 1998 ; 16 : 1388-96.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8.
5. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002 ; 13 : 1539-49.
6. Bardet E, Moro-Sibilor D, Le Chevalier T, Massard G, Douillard JY, Theobald S et al. Standards, Options and Recommendations for the management of locally advanced non small cell lung carcinoma. Bull Cancer 2001 ; 88 : 369-87.
7. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advance ovarian cancer. J Clin Oncol 2000 ; 18 : 3084-92.
8. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al. Phase III trial of carboplatine and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003 ; 21 : 3194-200.
9. Kerbrat P, Lhomme C, Fevers B. SOR for initial management with malignant ovarian epithelial tumors. Presse Med 2000 ; 29 : 2116-27.
10. André T, Louvet C, Maindrauk-Goebel F, Gramont AD. Oxaliplatin in combination with 5-fluoro-uracil and folinic a treatment of metastatic colorectal cancer. Bull Cancer 2001 ; 88 : S20-5.
11. Tournigand C, André T, Louvet C, Quinaux E, Achille E, Lledo G, et al. Folfiri followed by Folfox versus Folfox followed by Folfiri in metastatic colo-rectal cancer (MCRC). J Clin Oncol 2004 (in press).
12. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin : interim results of a phase III trial. J Clin Oncol 2003 ; 21 : 2059-69.
13. Bouche O, Raoul JL, Giovanini M, Etienne PL, Bedenne L, Lledo G et al. Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD 9803. Proc Am Soc Clin Oncol 2003 ; 22 : 258 [abstract 1033].
14. Nabholtz JM, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Vogel C et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients : interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002 ; 21 : 36 a, [abstract 141].
15. De Gramont A, Boni C, Navarro M, Tabernero J, Hickisch T, Bridgewater J et al. Oxaliplatin/5-fu/lv in adjuvant colon cancer : results of rhe international randomized "Mosaic" trial. Proc Am Clin Oncol 2003 ; 22 : 253 [abstract 1015].
16. Ranchère JY. Analyse critique des recommandations comme référentiel en pratique clinique. Bull Cancer 1998 ; 85 : 895-8.